Active Ingredient History
Phenobarbital, also known as phenobarbitone or phenobarb, sold under the brand name Luminal among others, is a medication of the barbiturate type. It is recommended by the World Health Organization (WHO) for the treatment of certain types of epilepsy in developing countries. In the developed world, it is commonly used to treat seizures in young children, while other medications are generally used in older children and adults. In developed countries it is used for veterinary purposes. It may be used intravenously, injected into a muscle, or taken by mouth. The injectable form may be used to treat status epilepticus. Phenobarbital is occasionally used to treat trouble sleeping, anxiety, and drug withdrawal and to help with surgery. It usually begins working within five minutes when used intravenously and half an hour when administered by mouth. Its effects last for between four hours and two days. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Conscious Sedation (approved 1912)
Acute Febrile Encephalopathy (Phase 2)
Acute Kidney Injury (Phase 4)
Alcohol Withdrawal Delirium (Phase 4)
Analgesics, Opioid (Phase 3)
Anxiety Disorders (Phase 3)
Astrocytoma (Phase 1)
Brain Injuries (Phase 4)
Brain Injuries, Traumatic (Phase 4)
Brain Ischemia (Phase 4)
Coma (Phase 4)
Dementia (Phase 3)
Depression (Phase 3)
Drug Resistant Epilepsy (Phase 4)
Epilepsy ()
Epilepsy, Benign Neonatal (Phase 3)
Glioblastoma (Phase 1)
Glioma (Phase 4)
Gliosarcoma (Phase 1)
Heart Arrest (Phase 4)
Hypoxia, Brain (Phase 4)
Hypoxia-Ischemia, Brain (Phase 4)
Infant, Low Birth Weight (Phase 3)
Infant, Newborn (Phase 3)
Infant, Premature (Phase 3)
Infant, Small for Gestational Age (Phase 3)
Intestinal Neoplasms (Phase 1)
Intracranial Hemorrhages (Phase 4)
Lymphoma (Phase 1)
Neonatal Abstinence Syndrome (Phase 3)
Neoplasms (Phase 1)
Neutropenia (Phase 1)
Oligodendroglioma (Phase 1)
Pediatrics (Phase 3)
Persistent Vegetative State (Phase 4)
Pharmacokinetics (Phase 4)
Psychophysiologic Disorders (Phase 3)
Renal Insufficiency (Phase 4)
Schizophrenia (Phase 3)
Seizures (Phase 4)
Status Epilepticus (Phase 3)
Stroke (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
